DEF 14A: Vericel Reports Strong 2023 Results, Anticipates Continued Growth in 2024

Vericel Corporation announces a strong financial year in 2023, with significant revenue growth and key business milestones, setting the stage for continued success in 2024.

Summary

• Vericel Corporation reported a strong financial performance in 2023, with total revenue increasing by 20% to over $197 million.
• MACI revenue grew by 25% to nearly $165 million.
• Adjusted EBITDA increased by 40% to approximately $34 million.
• The company commercially launched NexoBrid in the United States and the FDA accepted the submission to expand the MACI label to include arthroscopic delivery.
• The company is approaching 50% penetration of its 5,000 target surgeons for MACI.
• The company plans to expand its surgeon target base to approximately 7,000 surgeons upon the expected launch of MACI Arthro later this year.
• The company is on track to initiate a MACI Ankle clinical study in 2025.
• The company estimates the addressable market for MACI Ankle to be $1 billion.
• The company estimates the addressable market for NexoBrid to be $600 million.
• The company expects another year of strong revenue growth and further improvement in profitability metrics in 2024.
• The company anticipates the launch of MACI Arthro in the third quarter of 2024.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong financial results, successful product launches, and promising pipeline developments, indicating a strong and confident sentiment.

Positives

• Strong revenue growth in 2023, with a 20% increase in total revenue and a 25% increase in MACI revenue.
• Significant growth in profitability metrics, with a 40% increase in adjusted EBITDA.
• Successful commercial launch of NexoBrid in the United States.
• FDA acceptance of the submission to expand the MACI label to include arthroscopic delivery.
• Advancement of lifecycle management initiatives for MACI, including the MACI Arthro program and the MACI Ankle clinical development program.
• Strong engagement with burn centers in the early phase of the NexoBrid launch.
• The company has $152.6 million in cash, restricted cash and investments and no debt as of December 31, 2023.

Future Outlook

Vericel anticipates another year of strong revenue growth and further improvement in profitability metrics in 2024, driven by continued strength across its portfolio and the first full year of NexoBrid on the market, with the anticipated launch of MACI Arthro in the third quarter expected to contribute more meaningfully to revenue growth in 2025 and beyond.

Management Comments

• Vericel delivered another strong year of financial and business results in 2023, generating top-tier revenue growth and even higher growth in our profitability metrics.
• Given the momentum in our business, the significant market opportunities for our products and our strong financial profile, we believe that Vericel is very well-positioned for sustained long-term growth in the years ahead.

Industry Context

Vericel is positioning itself as a leader in the advanced therapies market for sports medicine and severe burn care, differentiating itself through cell therapy and specialty biologic products with significant barriers to entry for competitors.

Comparison to Industry Standards

• Vericel's stock performance has increased approximately 72% between December 30, 2022 and March 8, 2024, outperforming the Nasdaq Biotechnology Index, the Russell 2000 Index and the average of its Proxy Statement Peer Group during that period.
• The company's peer group includes Agenus, Inc., Agios Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Anika Therapeutics, Inc., Artivion, Inc., AtriCure, Inc., AxoGen, Inc., Cardiovascular Systems, Inc., Corcept Therapeutics, Inc., Cryoport, Inc., Glaukos Corporation, Ironwood Pharmaceuticals, Inc., PTC Therapeutics, Inc., STAAR Surgical Company, Supernus Pharmaceuticals, Inc., and Vanda Pharmaceuticals, Inc.

Corporate Governance

Stakeholder Impact

• Shareholders benefit from the company's strong financial performance and increased shareholder value.
• Patients gain access to innovative advanced cell therapy and specialty biologics products.
• Employees benefit from comprehensive programs to support health and wellness, as well as internal development and advancement opportunities.

Next Steps

• Commercial launch of MACI Arthro expected during Q3 2024.
• Initiate MACI Ankle clinical study beginning in 2025.
• Continue to evaluate opportunities to manage the Company's environmental impact as we prepare to transition operations to our new facility.

Key Dates

Keywords

Vericel, MACI, NexoBrid, Epicel, Revenue Growth, EBITDA, Cartilage Repair, Burn Care, Arthroscopic Delivery, Clinical Study, FDA Approval, Financial Performance, Shareholder Value, Sports Medicine, Advanced Therapies